1 Min Read
June 5 (Reuters) - Immune Design Corp:
* Announced updated clinical and biomarker data for its lead immuno-oncology product candidates, CMB305 and G100
* Immune Design Corp - "CMB305 was well tolerated, with only one related grade 3 adverse event (AE)"
* Immune Design - in follicular NHL patients, intratumoral immunization with G100 induced objective responses (≥50% tumor reduction) in 44% of patients
* "G100 was well tolerated, with no related grade 3/4 AES in all three dose levels tested" Source text for Eikon: Further company coverage: